Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis

Jamie L. Harden; Leanne M. Johnson-Huang; Maria Francesca Chamian; Edmund Lee; Tillman Pearce; Craig L. Leonardi; Asifa Haider; Michelle A. Lowes; James G. Krueger

doi:10.1016/j.jaci.2014.05.046

Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis

Jamie L. Harden, Leanne M. Johnson-Huang, Maria Francesca Chamian, Edmund Lee, Tillman Pearce, Craig L. Leonardi, Asifa Haider, Michelle A. Lowes, James G. Krueger

Medicine

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Original language	English (US)
Pages (from-to)	553-556.e3
Journal	Journal of Allergy and Clinical Immunology
Volume	135
Issue number	2
DOIs	https://doi.org/10.1016/j.jaci.2014.05.046
State	Published - Feb 1 2015

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2014.05.046

Cite this

@article{489973fd6b3d459abdf875921e752f20,

title = "Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis",

author = "Harden, {Jamie L.} and Johnson-Huang, {Leanne M.} and Chamian, {Maria Francesca} and Edmund Lee and Tillman Pearce and Leonardi, {Craig L.} and Asifa Haider and Lowes, {Michelle A.} and Krueger, {James G.}",

note = "Funding Information: Disclosure of potential conflict of interest: J. L. Harden and M. A. Lowes have received research support from the National Institutes of Health / National Institute of Arthritis, Musculoskeletal and Skin Diseases (grant no. 1R01AR060222). L. M. Johnson-Huang has received research support from the Linda and Leonard Berkowitz Foundation . M. F. Chamian is employed at a private dermatological practice. T. Pearce is employed by PDF Biopharma and has received stock options as part of his compensation. C. L. Leonardi has received a fee for service as an investigator for PDL, Addvie, Amgen, Anacor, Celgene, Galderma, Janssen, Maruho, Merck, Novartis, Eli Lilly, Leo, Pfizer, Stiefel, and Tolmar; has consultant arrangements with Abbvie, Amgen, Dermira, Eli Lilly, Leo Pharmaceuticals, Pfizer, Sandoz, and UCB; and has received payment for lectures from Abbvie. J. G. Krueger has received research support, consulting fees, and provision of drug for the study from Protein Design Laboratory ; has consultant arrangements with Abbvie, Akros, Amgen, Astellas, Boehringer, Biogen-Idec, Janssen, Dermira, Eli Lilly, Genzyme-Sanofi, Leo Pharmaceutical, Merck, Novartis, and Pfizer; and has received research support from Akros , Amgen , Astellas , Boehringer , Biogen Idec , Centocor / Janssen , Dermira , Lilly , Genzyme-Sanofi , Merck , Novartis , and Pfizer . The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: M.A.L. and J.L.H. were supported by the National Institutes of Health (grant no. 1R01AR060222 ). L.M.J.-H. was supported by the Linda and Leonard Berkowitz Postdoctoral Fellowship . ",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.jaci.2014.05.046",

language = "English (US)",

volume = "135",

pages = "553--556.e3",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis

AU - Harden, Jamie L.

AU - Johnson-Huang, Leanne M.

AU - Chamian, Maria Francesca

AU - Lee, Edmund

AU - Pearce, Tillman

AU - Leonardi, Craig L.

AU - Haider, Asifa

AU - Lowes, Michelle A.

AU - Krueger, James G.

N1 - Funding Information: Disclosure of potential conflict of interest: J. L. Harden and M. A. Lowes have received research support from the National Institutes of Health / National Institute of Arthritis, Musculoskeletal and Skin Diseases (grant no. 1R01AR060222). L. M. Johnson-Huang has received research support from the Linda and Leonard Berkowitz Foundation . M. F. Chamian is employed at a private dermatological practice. T. Pearce is employed by PDF Biopharma and has received stock options as part of his compensation. C. L. Leonardi has received a fee for service as an investigator for PDL, Addvie, Amgen, Anacor, Celgene, Galderma, Janssen, Maruho, Merck, Novartis, Eli Lilly, Leo, Pfizer, Stiefel, and Tolmar; has consultant arrangements with Abbvie, Amgen, Dermira, Eli Lilly, Leo Pharmaceuticals, Pfizer, Sandoz, and UCB; and has received payment for lectures from Abbvie. J. G. Krueger has received research support, consulting fees, and provision of drug for the study from Protein Design Laboratory ; has consultant arrangements with Abbvie, Akros, Amgen, Astellas, Boehringer, Biogen-Idec, Janssen, Dermira, Eli Lilly, Genzyme-Sanofi, Leo Pharmaceutical, Merck, Novartis, and Pfizer; and has received research support from Akros , Amgen , Astellas , Boehringer , Biogen Idec , Centocor / Janssen , Dermira , Lilly , Genzyme-Sanofi , Merck , Novartis , and Pfizer . The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: M.A.L. and J.L.H. were supported by the National Institutes of Health (grant no. 1R01AR060222 ). L.M.J.-H. was supported by the Linda and Leonard Berkowitz Postdoctoral Fellowship .

PY - 2015/2/1

Y1 - 2015/2/1

UR - http://www.scopus.com/inward/record.url?scp=84922435198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922435198&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2014.05.046

DO - 10.1016/j.jaci.2014.05.046

M3 - Article

C2 - 25085340

AN - SCOPUS:84922435198

VL - 135

SP - 553-556.e3

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2

ER -

Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this